ACTG 179--COMPARISON OF TWO DOSAGE REGIMENS OF ORAL DAPSONE FOR PCP PROPHYLAXIS

ACTG 179——口服氨苯砜预防 PCP 的两种剂量方案的比较

• 批准号: 5224963
• 负责人: KENNETH MCINTOSH
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5224963
• 关键词: Pneumocystis carinii; Pneumocystis pneumonia; chemoprevention; child (0-11); clinical research; clinical trial phase I; dapsone; dosage; human subject; human therapy evaluation; microorganism disease chemotherapy; opportunistic infections; oral administration; pediatric AIDS

ACTG 179 is a Phase I/II, comparative, randomized, open-label, two-dose study of dapsone for PCP prophylaxis in HIV-infected infants and children 1 month to 12 years of age who are intolerant to trimethoprim-sulfamethoxazole. Children will be randomized to receive dapsone 1 mg/kg p.o. once daily or dapsone 4 mg/kg p.o. once weekly. Endpoints to be monitored include hematologic and dermatologic toxicity to dapsone.

ACTG 179是一种I/II期、比较性、随机、开放标签、两次给药 氨苯砜预防HIV感染婴幼儿PCP研究 1个月至12岁，不耐受 甲氧苄啶磺胺甲恶唑 儿童将随机接受 氨苯砜1 mg/kg p.o.每日一次或氨苯砜4 mg/kg p.o.每周一次。 监测的终点包括血液学和皮肤学毒性 给氨苯砜